PT

Pallavi Tripathi

Active Director Director DIN 10370245
DIN 10370245 First appointment Oct 2023 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 2 active board seats
Total affiliations 2 Since Oct 2023
Shareholding value β€’β€’β€’β€’ Premium profile

About Pallavi Tripathi

Data last updated:

Pallavi Tripathi is a Director at Snapify Pharmaceutical Private Limited (since 2023) and Managing Director at Snapzen Pharmaceutical Private Limited (since 2023). The companies operate in Pharma.

DIN 10370245
Primary Designation Director
Industry Pharma
First Appointment 26 Oct 2023
Oldest Company Age 3 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director23 Nov 20232023Active
Managing Director26 Oct 20232023Active

Board colleagues of Pallavi Tripathi

Directorship timeline

Open interactive timeline →
Snapify Pharmaceutical Private Limited
Snapzen Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Pallavi Tripathi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pallavi Tripathi

Pallavi Tripathi currently holds 2 directorships: Snapify Pharmaceutical Private Limited (Director, since 23 Nov 2023); Snapzen Pharmaceutical Private Limited (Managing Director, since 26 Oct 2023).

Pallavi Tripathi was first appointed on 26 Oct 2023 as Managing Director at Snapzen Pharmaceutical Private Limited.

The current boards of Pallavi Tripathi's companies include Manas Mani Pathak (Snapify Pharmaceutical Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available